Onartuzumab plus bevacizumab versus placebo plus bevacizumab in recurrent glioblastoma (GBM): HGF and MGMT biomarker data.

Author:

Cloughesy Timothy Francis1,Finocchiaro Gaetano2,Belda Cristobal3,Recht Lawrence4,Brandes Alba Ariela5,Pineda Estela6,Mikkelsen Tom7,Chinot Olivier L.8,Balana Carmen9,Macdonald David R.10,Westphal Manfred11,Hopkins Kirsten12,Weller Michael13,Liu Bo14,Bruey Jean-Marie14,Verret Wendy14

Affiliation:

1. UCLA, Los Angeles, CA

2. Istituto Neurologico Carlo Besta, Milan, Italy

3. Centro Integral Oncológico Clara Campal, University Hospital MN Sanchinarro, Madrid, Spain

4. Stanford University School of Medicine, Stanford, CA

5. Department of Medical Oncology, Azienda USL, Bologna, Italy

6. Hospital Clinic of Barcelona, Barcelona, Spain

7. Henry Ford Health System, Detroit, MI

8. Aix-Marseille University, Department of Neuro-Oncology, University Hospital La Timone, Marseille, France

9. Institut Catala Oncologia. Hospital Germans Trias I Pujol, Badalona/Barcelona, Spain

10. London Regional Cancer Program, Western University, London, ON, Canada

11. Department of Neurosurgery, Hamburg, Germany

12. Bristol Haematology and Oncology Center, Bristol, United Kingdom

13. Department of Neurology, University Hospital Zurich, Zurich, Switzerland

14. Genentech, Inc., San Francisco, CA

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3